Evidence map›Paper›PMID 38276802›Full record

ArticleInternational journal of environmental research and public health2023

Initial Validation of a Behavioral Phenotyping Model for Substance Use Disorder.

Lori Keyser-Marcus, Tatiana Ramey, James M Bjork, Caitlin E Martin, Roy Sabo, F Gerard Moeller

Abstract read
In one paragraph

Article in International journal of environmental research and public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lori Keyser-MarcusDepartment of Psychiatry, Division of Addictions, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA 23219, USA.
Tatiana RameyDivision of Therapeutics and Medical Consequences, National Institute on Drug Abuse (NIDA), Gaithersburg, MD 20877, USA.
James M BjorkDepartment of Psychiatry, Division of Addictions, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA 23219, USA.ORCID 0000-0003-0593-3291
Caitlin E MartinDepartment of Obstetrics and Gynecology, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA 23219, USA.
Roy SaboDepartment of Biostatistics, Virginia Commonwealth University, Richmond, VA 23219, USA.
F Gerard MoellerDepartment of Psychiatry, Division of Addictions, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA 23219, USA.

Funding

Research Supplement to Promote Diversity in Health Related ResearchUL1TR002649 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2018 to 2022
$19.1M
Preclinical Assessment of Compounds for Cocaine Use Disorder (CocUD)U54DA038999 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2014 to 2018
$6.8M
Olanzapine Augmentation in OUD Patients on Buprenorphine-Naloxone with Comorbid Symptoms of Serious Mental Illness (SMI): A Prospective Observational 8-week Pilot StudyUG1DA050207 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI ARIAS, ALBERT JOSEPH, MOELLER, FREDERICK GERARD · 2020 to 2024
$3.1M
Adaptation and Refinement of a Clinically Applicable Phenotypic Battery to Individualize Opioid Use Disorder Treatment for Women Through the Postpartum PeriodK23DA053507 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI MARTIN, CAITLIN EILEEN · 2021 to 2025
$1.0M
NCATS NIH HHS UL1 TR002649NCATS NIH HHS UL1TR002649NIDA NIH HHS K23 DA053507NIDA NIH HHS U54 DA038999NIDA NIH HHS U54DA038999NIDA NIH HHS UG1 DA050207
6 · The paper itself

Abstract

Standard nosological systems, such as DSM-5 or ICD-10, are relied upon as the diagnostic basis when developing treatments for individuals with substance use disorder (SUD). Unfortunately, the vast heterogeneity of individuals within a given SUD diagnosis results in a variable treatment response and/or difficulties ascertaining the efficacy signal in clinical trials of drug development. Emerging precision medicine methods focusing on targeted treatments based on phenotypic subtypes rather than diagnosis are being explored as alternatives. The goal of the present study was to provide initial validation of emergent subtypes identified by an addiction-focused phenotyping battery. Secondary data collected as part of a feasibility study of the NIDA phenotyping battery were utilized. Participants completed self-report measures and behavioral tasks across six neurofunctional domains. Exploratory and confirmatory factor analysis (EFA/CFA) were conducted. A three-factor model consisting of negative emotionality, attention/concentration, and interoception and mindfulness, as well as a four-factor model adding a second negative emotion domain, emerged from the EFA as candidate models. The CFA of these models did not result in a good fit, possibly resulting from small sample sizes that hindered statistical power.

Indexed as

Behavior, AddictiveMindfulnessSubstance-Related DisordersHumansMotivationSelf Reportaddictiondeep phenotypingfactor analysistreatment matching

Identifiers

PMID38276802
PMCPMC10815773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.